CAPR (Capricor Therapeutics) PS Ratio: (As of Jun. 28, 2026)


CAPR Capricor Therapeutics Inc CAPR
37 GF Score
Price $26.41
GF Value $4.87
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Capricor Therapeutics PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Capricor Therapeutics's share price is $26.41. Capricor Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00. Hence, Capricor Therapeutics's PS Ratio for today is .

The historical rank and industry rank for Capricor Therapeutics's PS Ratio or its related term are showing as below:

During the past 13 years, Capricor Therapeutics's highest PS Ratio was 671.11. The lowest was 2.41. And the median was 19.15.

CAPR's PS Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 9.155
* Ranked among companies with meaningful PS Ratio only.

Capricor Therapeutics's Revenue per Sharefor the three months ended in Mar. 2026 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00.

During the past 12 months, the average Revenue per Share Growth Rate of Capricor Therapeutics was -100.00% per year.

During the past 13 years, Capricor Therapeutics's highest 3-Year average Revenue per Share Growth Rate was 285.90% per year. The lowest was -73.10% per year. And the median was -36.25% per year.

Back to Basics: PS Ratio


Capricor Therapeutics  (NAS:CAPR) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Capricor Therapeutics PS Ratio Related Terms


Capricor Therapeutics PS Ratio Historical Data

* Premium members only.

The historical data trend for Capricor Therapeutics's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Capricor Therapeutics PS Ratio Chart

Capricor Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 266.36 37.12 5.20 21.84 0.00

Capricor Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.42 31.23 28.84 0.00 0.00

CAPR vs SNDX, SLS, AGIO: PS Ratio Comparison

For the Biotechnology subindustry, Capricor Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Capricor Therapeutics PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Capricor Therapeutics's PS Ratio distribution charts can be found below:

* The bar in red indicates where Capricor Therapeutics's PS Ratio falls into.


CAPR
37GF Score
Capricor Therapeutics Inc CAPR
PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Capricor Therapeutics PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Capricor Therapeutics's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=26.41/0
=

Capricor Therapeutics's Share Price of today is $26.41.
Capricor Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.

Is Capricor Therapeutics (CAPR) Overvalued in 2026?

Based on GuruFocus' analysis, Capricor Therapeutics stock appears to be overvalued. The current stock price of $26.41 is trading 442.3% above its estimated GF Value™ of $4.87. GuruFocus considers Capricor Therapeutics to be Significantly Overvalued.

Key valuation signals for CAPR:

  • PS Ratio:
  • GF Value™: $4.87 vs. price of $26.41 (442.3% above fair value)
  • GF Score™: 37/100 with 3 warning signs

No single metric tells the full story. See the CAPR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Capricor Therapeutics Business Description

Other Exchanges 4LN2:Germany
Address 10865 Road to the Cure, Suite 150, San Diego, CA, USA, 92121
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
37GF Score

Get the complete analysis for CAPR

PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$26.41
Price
$4.87
GF Value